Investments, Funding & Disinvestment

Under the agreement, Servier will take control of Edgewise Therapeutics’ muscular dystrophy portfolio, including its lead candidate sevasemten.

The initiative focuses on expanding genomic sequencing capacity, improving molecular diagnostics, and enhancing real-time disease surveillance across African health systems.

The financing will also reinforce critical pillars of outbreak control, including disease surveillance, laboratory diagnostics, infection prevention and control, and cross-border coordination mechanisms.

The plan targets key pillars of outbreak control, including emergency coordination, disease surveillance, laboratory diagnostics, infection prevention and control, and clinical case management.

Established in 2022, the collaboration combines CytomX’s Probody masking technology with Regeneron’s Veloci-Bi bispecific antibody platform.

The plan follows Arada’s acquisition of a controlling stake in Reem Hospital, marking the company’s entry into the healthcare sector as it expands its presence across non-residential industries.

The initiative will also involve coordination with World Health Organization, Africa Centres for Disease Control and Prevention, and UNICEF to ensure alignment with national outbreak response plans and immunization priorities.

The equipment was officially received by Ministry of Health Permanent Secretary for Donor Coordination, Dr. George Sinyangwe, during a handover ceremony attended by senior government officials and public health leaders.

This new allocation builds on earlier support, which includes US$350 million in Ebola response and broader humanitarian assistance across the DRC, South Sudan, and Uganda.

The funding will support three promising vaccine candidates being developed by Moderna, the University of Oxford in partnership with the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI).